Successful applications to date for access to the free TRANSVAC services

Access to the free TRANSVAC services has been approved by the Scientific Advisory Committee and the User Selection Panel for the following projects.

Results of the first call for applications (1101-1)

	Applicant / User	Access granted to	Access units provided	Project
1	Statens Serum Institut (SSI), Copenhagen / Professor Peter Andersen	Experimental Non-human primate model facility, Biomedical Primate Research Centre (BPRC)	18	CD4/8 responses by CAF - Evaluation of the immunogenicity and tolerability of an antigenic formulation in CD4 T-cell inducing CAF01 and CD4/CD8 T-cell inducing CAF05 adjuvant upon simultaneous muco-parenteral compared to traditional parenteral delivery in rhesus macaques
2	Themis Bioscience, Vienna / Dr Katrin Ramsauer	Helmholtz Centre for Infection Research, Germany- ILLUMINA Deep Sequencing	10	MVDVAX- A single tetravalent live attenuated recombinant Measles Virus Vaccine against DENGUE
3	Université de Lyon, Faculté de Médecine Saint Etienne / Dr Stéphane Paul	Vaccine formulation laboratory - World Health Organization Collaborating Centre - University of Lausanne	9	MUCOSTIM - Evaluation of adjuvant formulation in the induction of mucosal immune responses against HIV after subcutaneous or intramuscular vaccination with p24 antigen encoated on PLA particles
4	Trinity College Dublin / Dr Karen Misstear	Vaccine formulation laboratory - World Health Organization Collaborating Centre - University of Lausanne	5	TARGET-PART-QS21 - Development of potent mucosal vaccines by combining an effective targeting agent with immunostiumlatory particulate adjuvants

Results of the second call for applications (1104-2)

	Applicant / User	Access granted to	Access units provided	Project
1	INSERM, Institut Pasteur de Lille / Dr Jean-Claude Sirard	Max Planck Institute for Infection Biology, Germany - AGILENT Microarrays	1	FLAGMARK – Transcriptional analysis of flagellin-mediated adjuvant activity: defining predictive biomarkers of efficacy in blood samples
2	The Jenner Institute, Oxford / Professor Adrian Hill	Vaccine formulation laboratory - World Health Organization Collaborating Centre - University of Lausanne	5	COM_VAX (CombiVAX) – Combination (vector-adjuvant-protein) vaccine against malaria
3	University College Cork Dr Anne Moore	Central Veterinary Institute of Wageningen UR (former partner: ID-Lelystad (IDL), Animal Sciences Group of Wageningen UR) – Large Animal studies	1	ImmuPatch – Pre-clinical Testing of Influenza Vaccine Incorporated in Dissolvable ImmuPatch Microneedle Arrays

Results of the second call for applications (1104-3)

	Applicant / User	Access granted to	Access units provided	Project
1	Academy of Sciences of Czech Republic, Ceske Budejovice, Czech Republic / Dr Michail Kotsyfakis	ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany	TBD	DUALVACANTIRICINUS The discovery of candidate 'dual' antigens for vaccine development by deep sequencing of Ixodes ricinus salivary and midgut transcriptomes
2	Glycovaxyn, Schlieren, Switzerland / Dr Cristina Alaimo	Experimental murine validation platform ,Helmholtz Centre for Infection Research, Germany	TBD	GVXN Pn4-EPA_1 Evaluation of the immunogenicity and functionality of a glycoprotein vaccine against Streptococcus pneumoniae serotype 4
3	Institute of Immunology Inc. Zagreb, Zagreb, Croatia/ Dr Jelena Ivancic-Jelecki	ILLUMINA Deep Sequencing, Helmholtz Centre for Infection Research, Germany	TBD	MUMPSVAC The influence of viral population diversity on safety and immunogenicity of licensed mumps vaccine strain
4	Biomedical Primate Research Centre Rijswijk, The Netherlands / Dr Ed Remarque	Vaccine formulation laboratory, World Health Organization Collaborating Centre - University of Lausanne, Switzerland	9	rAMA1_VAC Formulation of model vaccines for the PHARVAT adjuvant harmonization platform

Apply now for the 5th call for applications which closes on 31 January 2012!

TRANSVAC